Soap Box, page-29

Thanks again for the additional info @@wasko

I had seen this contract agreement in my early research but I've since re-read it to try and fully wrap my head around it. Seems like a very positive business relationship that ECS has with Sun Pharma and lots to like about the contract agreement. With regards to the C02 Extractor, I'm assuming based off the information you provided that the unit has been commissioned? I noticed in the agreement with Cannvalante that commissioning of the unit was expected to be completed in early 2023 as per the snapshot below.



ECS then mention in the FY22 Annual Report that the partnership would deliver substantial savings from m2023 which I assume to be mid 2023.



I've looked in the quarterly reports but haven't been able to find any mention of commissioning completion. Thought it would have been mentioned in a quarterly or a separate announcement as it triggers the additional 3 year supply within the Cannvalate agreement which will generate decent additional annual revenue.

I wasn't sure if the commissioning also triggered the supply of cannabis to Sun Pharma as well but I would have assumed so.


Anyways, all that to say that I feel like the commissioning of the C02 extractor was an important milestone worth mentioning somewhere unless I've missed it. I'm keen to compare the receivables number in the annual report to confirm this has been completed!

On the trial front, I am very keen to see the results of this and the potential benefits. I saw a response that Nan posted to a question within the investor hub, which related to the cost smoothing and production timelines. Your explanation has helped me understand it a bit further, so thank you once again.

I had seen the VESIsorb details in the latest quarterly but it definitely went over my head I'll take a closer look at it and see if I can wrap my head around it